UBT251
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
The United Bio-Technology (Hengqin) Co · Phase 2 · Recruiting · Enrollment 333
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part A - UBT251 | n/r | n/r | n/r | n/r |
| Part A - placebo | n/r | n/r | n/r | n/r |
| Part B - Arm A (UBT251) | n/r | n/r | n/r | n/r |
| Part B - Arm B (UBT251) | n/r | n/r | n/r | n/r |
| Part B - Arm C (UBT251) | n/r | n/r | n/r | n/r |
| Part B - Arm D (UBT251) | n/r | n/r | n/r | n/r |
| Part B - Arm E (UBT251) | n/r | n/r | n/r | n/r |
| Part B - placebo | n/r | n/r | n/r | n/r |
| Part C - UBT251 dose 1 | n/r | n/r | n/r | n/r |
| Part C - UBT251 dose 2 | n/r | n/r | n/r | n/r |
| Part C - UBT251 dose 3 | n/r | n/r | n/r | n/r |
Not shown
- Part A - UBT251: endpoint not reported
- Part A - placebo: endpoint not reported
- Part B - Arm A (UBT251): endpoint not reported
- Part B - Arm B (UBT251): endpoint not reported
- Part B - Arm C (UBT251): endpoint not reported
- Part B - Arm D (UBT251): endpoint not reported
- Part B - Arm E (UBT251): endpoint not reported
- Part B - placebo: endpoint not reported
- Part C - UBT251 dose 1: endpoint not reported
- Part C - UBT251 dose 2: endpoint not reported
- Part C - UBT251 dose 3: endpoint not reported